NEW YORK and CLEVELAND, Oct. 16, 2017 (GLOBE NEWSWIRE) — Abeona Therapeutics Inc. (Nasdaq:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene and cell therapies for life-threatening rare diseases, today announced the pricing of an underwritten public offering of five million shares of common stock at a public offering price of $16.00 per share.